Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
(NQ:
)
N/A
UNCHANGED
Last Price
Updated:
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Apricus Biosciences Announces Completion of Transfer of the Marketing Authorizations for Vitaros® in Finland and Denmark to Ferring Pharmaceuticals
September 20, 2016
Ferring Demonstrates Continued Progress Towards Building the Vitaros Brand in Europe
From
GlobeNewswire News Releases
Drug Makers Stocks Technical Reports -- Pernix Therapeutics, Synergy Pharma, Novo Nordisk, and Apricus Biosciences
September 15, 2016
From
PR Newswire
Top Performing Industries For September 14, 2016
September 14, 2016
At 10:30 am, the Dow rose 0.48 percent to 18,153.83, the broader Standard & Poor's 500 index moved up 0.56 percent to ...
Tags
Markets
Intraday Update
AAPL
From
Benzinga
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Argentina
September 08, 2016
First Vitaros Approval in Latin America, Registrations Also Filed in Mexico and Colombia
From
GlobeNewswire News Releases
Apricus Biosciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
September 07, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will...
From
GlobeNewswire News Releases
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Portugal, Ireland and Poland by Recordati
September 06, 2016
To be Commercialized in Portugal and Ireland as Vitaros® and in Poland as Vytaros®
From
GlobeNewswire News Releases
BRIEF-Apricus Biosciences says gets $4.5 mln in upfront payments from Ferring
August 15, 2016
* Company's partner in United Kingdom, has received United Kingdom marketing authorization for Vitaros
Tags
companyNews
From
Reuters: Company News
Apricus Biosciences Announces Completion of Transfer of the United Kingdom Marketing Authorization for Vitaros® to Ferring Pharmaceuticals
August 15, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Ferring Pharmaceuticals, the Company’s new partner...
From
GlobeNewswire News Releases
Apricus Biosciences Announces Completion of Transfer of Vitaros® German Marketing Authorization to Ferring Pharmaceuticals
August 10, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Ferring Pharmaceuticals, the Company’s new partner...
From
GlobeNewswire News Releases
18 Biggest Mid-Day Losers For Friday
August 05, 2016
Computer Programs & Systems, Inc. (NASDAQ: CPSI) tumbled 30 percent to $27.36 after the company posted ...
Tags
BMY
News
Benzinga
From
Benzinga
Worst Performing Industries For August 5, 2016
August 05, 2016
The Dow rose 0.75 percent to 18,490.22, while the NASDAQ composite index gained 0.99 percent to 5,217.26. The broader Standard ...
Tags
News
MCZ
APRI
From
Benzinga
Apricus Biosciences Provides Corporate Update and Second Quarter Financial Results
August 04, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the second quarter of 2016 and...
From
GlobeNewswire News Releases
Apricus Biosciences to Present at the Canaccord Genuity 36th Annual Growth Conference
August 03, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will...
From
GlobeNewswire News Releases
Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call
August 01, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's second quarter 2016 financial results...
From
GlobeNewswire News Releases
Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon
July 27, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Republic of Lebanon Ministry of Public Health...
From
GlobeNewswire News Releases
BRIEF-Apricus Biosciences expands existing partnership with Ferring Pharmaceuticals
July 25, 2016
* Apricus biosciences inc says apricus and sandoz agree to mutually terminate license agreement
Tags
companyNews
From
Reuters: Company News
Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals in Europe and Asia
July 25, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has further expanded its exclusive distribution...
From
GlobeNewswire News Releases
BRIEF-Apricus Biosciences enters into common stock purchase agreement with Aspire Capital
July 06, 2016
* Apricus Biosciences enters into common stock purchase agreement with Aspire Capital
Tags
companyNews
From
Reuters: Company News
Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital
July 06, 2016
$7.0 Million Equity Facility with Existing Long-Term Shareholder
From
GlobeNewswire News Releases
BRIEF-Apricus Biosciences reports Q1 loss per share of $0.05
May 09, 2016
* To continue to reduce operating expenses with goal of achieving reductions of about 30% in 2016, 60% in 2017 compared to 2015
Tags
companyNews
From
Reuters: Company News
Apricus Biosciences Provides Corporate Update and First Quarter Financial Results
May 09, 2016
Vitaros® U.S. NDA Re-Submission on Schedule for 3Q 2016
From
GlobeNewswire News Releases
CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population
May 03, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced it will host a Vitaros® and erectile dysfunction (“ED”)...
From
GlobeNewswire News Releases
Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population
May 03, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced it will host a Vitaros® and erectile dysfunction (“ED”)...
From
GlobeNewswire News Releases
Apricus Biosciences to Announce Corporate Update and First Quarter 2016 Financial Results
May 03, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's first quarter 2016 financial results...
From
GlobeNewswire News Releases
Apricus Biosciences Updates Strategic Corporate Objectives
April 06, 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, updated its strategic objectives today to include its plans to...
From
GlobeNewswire News Releases
Stocks Hitting 52-Week Lows
March 30, 2016
Cellectar Biosciences Inc (NASDAQ: CLRB) shares fell 7.75 percent to touch a new 52-week low of $3.25. Cellectar Biosciences shares ...
Tags
Markets
Intraday Update
CLRB
From
Benzinga
Apricus Biosciences reports disappointing results
March 28, 2016
Apricus Biosciences Inc. (Nasdaq: APRI) reported disappointing results from a Phase 2b study of fispermifene to treat symptomatic secondary hypogonadism sending the stock price plummeting 64 cents to...
From
MarketMinute.com Stock News
Mid-Afternoon Market Update: Dow Jumps 50 Points; Pandora Shares Slide
March 28, 2016
Toward the end of trading Monday, the Dow traded up 0.29 percent to 17,566.31 while the NASDAQ gained 0.09 percent to 4,777.83. The ...
Tags
P
ACAD
Intraday Update
From
Benzinga
Apricus Biosciences Plunges 50% Following 'Disappointing' Phase 2B Data
March 28, 2016
Shares of Apricus Biosciences Inc (NASDAQ: APRI) plunged more than 50 percent on Monday after the company disclosed ...
Tags
News
apricus biosciences
Fispemifene
From
Benzinga
Mid-Day Market Update: Qlik Technologies Surges Amid Potential Sale; VirtualScopics Shares Decline
March 28, 2016
Midway through trading Monday, the Dow traded down 0.09 percent to 17,500.19 while the NASDAQ declined 0.20 percent to 4,763.90. The ...
Tags
News
Mid/Day Market Update
CALM
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.